2018 was a strong year for our Tiara and Reducer product platforms. Both have achieved significant therapy development milestones, putting Neovasc on a stronger foundation from which to continue advancing these products commercially. We also have a clear value creation strategy for patients, employees, and investors. All of this is really good news for our outlook.
Investor Overview
Latest News
Updates on Reducer and Tiara Programs will be presented at Advanced Cardiovascular Intervention 2020 Meeting
> read full release
Financial Report Archives
2019 Financial Reports
News Release Archives
2020 News Releases
- Q1
- Q2
- Q3
- Q4
Share Information
Auditor
Grant Thornton LLP, Vancouver, BC
Legal Counsel
Blakes LLP, Vancouver, BC
Transfer Agent
Computershare, Vancouver, BC
Investor Relations
Chris Clark, Chief Financial Officer
investors@neovasc.com
To automatically receive news updates